

Betel Nut and Arecoline: Past, Present, and Future Trends

Zisis Kozlakidis¹, Io Hong Cheong,² Hui Wang²

¹Laboratory Services and Biobanking, International Agency for Research on Cancer, World Health Organization, Lyon, France

²State Key Laboratory of Oncogenes and Related Genes, Centre for Single-Cell Omics, School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, China

Address correspondence to Zisis Kozlakidis (kozlakidisz@iarc.fr).

Source of Support: None. Conflict of Interest: None.

Received: May 25, 2022; Revision Received: Jul 18, 2022; Accepted: Jul 19, 2022

Kozlakidis Z, Cheong IH, Wang H. Betel nut and arecoline: Past, present, and future trends. *Innov Dig Health Diagn Bio.* 2022; 2:64–72. DOI: 10.36401/IDDB-22-05.

This work is published under a CC-BY-NC-ND 4.0 International License.

ABSTRACT

The areca nut, commonly known as betel nut, has been the subject of consistent scientific study over the past 5 decades. Betel nut is a natural compound chewed for its psychostimulating effects. Arecoline, the primary alkaloid of betel nut, is a muscarinic acetylcholine receptor agonist producing cholinergic effects on the parasympathetic nervous system and a psychoactive agent, contributing to the psycho-stimulating effects. Importantly the betel nut use is also associated with oral leucoplakia, submucous fibrosis, and squamous cell carcinoma. This narrative review explores the past, present, and future aspects of betel nut use, its historical applications, the development of biomarkers research, its health value concerns, and health economic impacts.

Keywords: betel nut, arecoline, carcinogenic, areca nut, south Asia

INTRODUCTION

The areca nut is the seed of the areca palm (*Areca catechu*), growing in the tropical Pacific, Southeast and South Asia, and parts of east Africa. It is commonly known as betel nut and has been the subject of consistent scientific study over the past 5 decades. Betel is a compound of natural substances chewed for its psycho-stimulating effects. Betel is composed of the nut of the areca palm, the leaf of the betel pepper (Piper betel), and lime (calcium hydroxide). Approximately 200 million persons chew betel regularly throughout the western Pacific basin Southeast and South Asia, and betel nut use altogether is estimated to involve as much as 10–20% of the global population.^[1,2] Only three substances (nicotine, ethanol, and caffeine) are consumed more widely than betel or are considered more commonly addictive.^[2] When betel is chewed, it produces mild psychoactive and cholinergic effects.

The major chemical components of betel nut are polyphenols, including tannins and alkaloids. Arecoline, the primary alkaloid, is a muscarinic acetylcholine receptor agonist linked to producing the cholinergic effects on the parasympathetic nervous system.^[3] Chewing the betel nut results in copious production of a blood-

red saliva that can stain oral structures. After years of chewing, the teeth may become red-brown to nearly black. Betel nut use is associated with oral leucoplakia, submucous fibrosis, and squamous cell carcinoma.^[4] Use of betel is discouraged in high-income countries because of its reported carcinogenic and perceived dysesthetic properties; nevertheless, betel nut is widely available in the West.

This narrative review explores the past, present, and future aspects of betel nut use and arecoline in relation to ongoing research and development of biomarkers for preventing potential adverse effects of longer-term use, with a greater focus on current and future prospects. The review contains data that have been collected by reviewing the international scientific literature in English. As such, there might be further reports within other languages that might not be visible when applying international search engines (e.g., PubMed). Thus, this narrative review should be considered indicative of the current state-of-the-art, but not necessarily exhaustive.

Looking at the Past Work

Early Focus on Epidemiology

Most published studies so far have focused on the negative health impact(s) following regular consump-

tion. Historically, the first report linking betel nut consumption and cancer appeared in the *British Medical Journal* in 1924^[5] and the *Indian Medical Gazette* in 1926,^[6] as India was under British rule at that time. These two reports were followed by sporadic reports on the same principle in subsequent decades. Most would be case reports of chronic users and the side effects of consistent use over a long period of time at the individual level, complemented by some very general epidemiologic reports on the geographic areas where betel nut use would be prevalent among the population.^[7–9] These reports did not form a connected body of work, for example where one cohort of patients would be followed through for a number of years, yet they were useful snapshots of the observations in the field.

In the early 1950s, the US Pacific Medical services would publish the first attempt at a scientific description of the consequences of chronic betel nut use. These would be a short series of manuscripts where the main population under investigation were natives in the Pacific islands under US jurisdiction (e.g., in Guam),^[9–12] driven by scientists and medical professionals who were stationed locally. In the 1960s, the use of betel nut was investigated from the perspective of psychiatric side effects, still in very isolated cases and populations in the Pacific islands (e.g., 1966 in Papua-New Guinea).^[13] The first report relating to China in the international English scientific literature comes from Taiwan in 1964 and viewed in relation to oral cancer incidence, followed up by a second publication in 1966.^[14,15]

It is important to note that all the previously mentioned reports were isolated in nature. For example, they referred to specific patient cases (case studies, e.g., in 1970),^[16] specific isolated communities (e.g., in Vietnam [1967],^[17] Ceylon [1967],^[18] India [1967],^[19] New Guinea [1968],^[20] Malaysia [1960]^[21]), or specific types of cancer that were relevant to the expertise of the investigator.^[22, 23] In other words, for 3 decades there was sporadic reporting, and no consistent international monitoring or an international study using harmonized protocols until the 1980s. The study of betel nut was almost always as part of wider studies on cancer, i.e., all other aspects that would currently be included in population-wide studies (e.g., socioeconomic benefits) or biomarkers development for cancer detection were completely absent until a limited study in 1967^[24] and two brief reports on potential benefits in 1969.^[25,26]

Chemical and Biochemical Investigations

The first investigation on the active chemical compounds of betel nut use was published in *Nature* in 1971, focusing on the effects of dimethyl sulfoxide (DMSO) in the oral tissues of laboratory model animals, specifically in hamsters.^[27] This was the starting point for experiments on the consequences of betel nut extracts on different laboratory animals, such as baboons (1972),^[28] rats (1972),^[29,30] and others.

Pharmacologic Investigations

The first review from a pharmacologic perspective was in 1976,^[31] where it recognized that the betel nut might have pharmacologic properties, based on practices from the Indian and Chinese traditional medicine systems. However, no evidence was provided, comparable to other ongoing studies to be able to support those claims. The existence of arecoline hydrobromide, as an active ingredient in the oral cavity, was also highlighted as having potential pharmacologic properties; circumstantial evidence was provided to this end from experimentation in dogs as an animal model.^[32]

It is important to note that in many of these studies, the authors did not differentiate among (1) the use of betel, (2) the use of tobacco and betel (not at the same time, by the same user), and (3) the use of tobacco and betel (at the same time and by the same user). This resulted in a number of publications where the impact of betel use could not be disassociated from the impact of chronic tobacco use in terms of health consequences.^[33] It was also shown that skin application of DMSO extracts of tobacco and of betel nut separately did not result in skin lesions in C17 mice, but when a mixed DMSO extract of tobacco and betel nut was used, skin papilloma and epidermoid carcinoma developed in some animals, including mice, hamsters, rats,^[34] and *Drosophila melanogaster*.^[35]

Consolidated Scientific Investigations

This ongoing situation, in which different studies in different populations or laboratory animal models were executed but lacked scientific transparency and comparability, was highlighted by a critical paper in *The Lancet* in 1979 with the title “Is ‘betel chewing’ carcinogenic?”^[36] The latter article called for international, harmonized studies for betel nut consumption and in particular on clear evidence relating to biochemical substances and their potential carcinogenic effect as a prelude to biomarkers development. As a result of this publication, a number of renewed efforts were made. Generally, from the 1980s to the 2000s efforts focused on (1) identifying the substances involved, (2) if these substances are biochemically active, (3) how they display this activity and under what conditions, (4) whether there is any direct correlation between betel nut use and cancer, and (5) if that is dose-dependent and for which substance (s).^[37–40] The introduction of omics technologies in the 2000s brought a renewed attention on the betel nut use field, as molecular studies could now be produced, and increasingly in a high-throughput manner. Regarding the scientific literature output as recorded in the PubMed scientific repository for the betel nut use, 2020 was the highest year in terms of publications, with a total of 173 scientific peer-reviewed manuscripts published. Compared with other cancer fields (e.g., colorectal cancer, cervical cancer) in which annual scientific publications are in the thousands of articles per year, this is a very low number and shows that even currently the volume of

registered scientific interest remains consistently marginal. Other recent reviews also report a similar low volume of scientific work relating to betel nut (e.g., 139 works identified on the epidemiology and use published from 1970 to 2019),^[41] although most of the studies were focused on the oncogenic properties of using betel nut.

MATERIALS AND METHODS

A narrative review approach has been chosen to investigate the topic of betel nut and potential impact of its use, as the aim was to provide a broad perspective and explore the general debates and developments on the topic, rather than implementing a systematic review approach, as the latter focuses on unique and specific queries, using explicit methodology.^[42] The search terms “areca nut” OR “betel nut” were used in the databases PubMed and Google Scholar since inception, to identify the published literature pool. More than 2000 items were identified, after filtering out conference proceedings, poster presentations, and non-English publications. Any articles that contained simple mention of betel nut, but not containing a dedicated investigation on the subject were also removed. The remaining abstracts were indexed by theme until thematic saturation was achieved, by the two authors (Z.K. and I.H.C.) and validated independently by the third one (H.W.). Primary references were used as much as possible over secondary references to previously published material.

It is important to note that there exist records and documentation in a number of local Asian languages relating to the application and use of betel nut. However, these have not been investigated, despite regular indications in the published English scientific literature that they do indeed exist. For example, the applications in traditional Chinese medicine (TCM) contain detailed records about betel nut application as part of prescribed herbal interventions. Modern records can be traced back within the *Chinese Medicine Pharmacology Handbook* since 1953,^[43] in which there are 60 betel nut-related formulations. Most of these formulations are used to treat digestive and endocrine diseases. Such applications require professional training before being prescribed and compliance to relevant regulations, and as per many other traditional medicine herbal-based formulations, they do rely on an evidence base, though the latter might not be directly comparable to the western medicine clinical research model. Some basic research stemming from those applications shows that the muscarinic cholinergic agonist arecoline stimulates the rat hypothalamic-pituitary-adrenal axis through a centrally mediated corticotropin-releasing hormone-dependent mechanism.^[44] Thus, there exist non-English sources that are potentially insightful and requiring further systematic research.

CONSIDERING THE PRESENT STATUS

Physiology

In terms of biochemical composition, recent reviews provide a summary view of the biochemical substances involved in betel nut consumption and the formation of oral cancer (oral submucous fibrosis [OSMF]). Although occasionally preceded by and/or associated with vesicle formation, OSMF is always associated with a juxta-epithelial inflammatory reaction followed by a fibro-elastic change of the lamina propria, with epithelial atrophy leading to stiffness of the oral mucosa and progressively causing trismus and inability to eat.^[45] Recent studies have also investigated the relationship between betel nut and cancers at sites other than in the oral cavity, such as colon cancer.^[46] As the most likely effects of betel nut use are of inflammatory nature, and therefore systemic, it is likely that betel nut use will be correlated with other cancers too, in particular where a sustained low-level inflammatory response can act as an oncogenic trigger mechanism. For example, chronic kidney disease, directly linked to kidney cancer and kidney failure, has been linked to sustained betel nut use in Chinese nationals.^[47] However, such associations are challenging, as they involve a systemic response (and hence multiple confounders), and this inherent challenge, despite the evidence that inflammation is an inherent component of cancer, seems to be ignored in most biomarker studies.^[48]

Oxidative stress and the generation of reactive oxygen species can drive affected cells to proliferation, senescence, or cell death. Chronic occurrence of events creating oxidative stress can lead to lesions in the oral cavity and could drive some of these lesions to malignancy. Thus, multiple features of the carcinogenic process have been observed in vitro and in situ in the oral cavity of betel quid chewers, as well as in model animals treated with the betel quid ingredients areca nut, arecoline, catechu, and slaked lime.^[49]

Biochemistry

Regarding the active substance of the betel nut, arecoline, it was demonstrated as causing the inhibition of both humoral and cell-mediated immune responses in mice. In addition, it was established that the betel nut contains approximately 11–26% tannins and 0.15–0.67% alkaloids, known to be both cytotoxic and genotoxic. Areca nut extract produced adverse effects on the proliferation of phytohemagglutinin-stimulated human lymphocytes in vitro, suggesting that there may be impaired immune surveillance in areca nut chewers. Arecoline modulates matrix metalloproteinases and their tissue inhibitors, as well as the activity of lysyl oxidase, which leads to the accumulation of collagen in oral mucosal fibroblasts.^[50] Furthermore, areca nut polyphenols inhibit collagenases and increase the cross-linkage of collagen, reducing its degradation. These biologic processes may underly the generation of oral submucous fibrosis, which could be further enhanced by the

presence of copper ions.^[51] Thus, a tentative pathway of the effects has been created; however, the authors of these studies note that in almost all cases, betel quid chewing was combined with smoking.^[52]

In vitro studies suggest that superoxide anions are generated because of auto-oxidation of polyphenols found in areca nut and catechu, and can be further enhanced by the alkaline pH of lime.^[53,54] The superoxide anion is then converted to H₂O₂, which reacts in the presence of transition metals, such as copper and iron, to generate hydroxy radicals. Copper and iron are present in microgram per gram amounts in the areca nut, pan masala, catechu, and slaked lime. This generation of radicals may be the critical step in carcinogenesis. In vitro studies demonstrated that areca nut and catechu in the presence of lime can induce oxidation of deoxyguanosine in DNA, a critical biomarker of oxidative stress and carcinogenesis,^[55] which could induce DNA strand breaks.^[56,57]

The International Agency for Research on Cancer considers betel nut use with and without tobacco to be carcinogenic to humans. One future option would be to set use limits and better inform risks to users, as per the models of public health information campaigns for tobacco use; however, such an approach would require further scientific evidence. In addition, some betel nut producers have developed plant varieties with a reduced amount of arecoline, yet there is uncertainty if such an approach would reduce the carcinogenic risks at all.

Biomarkers

Given the preceding biochemical characteristics and scientific developments, there has been a consistent effort in the past few years in the development of biomarkers that are appropriate for the betel nut use type (e.g., with or without tobacco), as well as bodily fluid (saliva). In addition, biomarkers might be used as key target indicators for public health cessation programs. Having said that, the biomarker discovery attempts remain at an early investigative stage and any future implementation within the public health set of routine operations remains a future probability. In such studies in Guam, in chewing saliva of users, the following substances were identified as potential biomarkers: guvacine, arecoline, guvacoline, arecaidine, nicotine, and chavibetol.^[58] The same potential biomarkers were confirmed in an independent pilot study; they could be detected in saliva and urine for short periods of time postexposure,^[59] and perhaps in buccal cells.^[60]

Although the preceding biomarkers might relate to measuring the level of consumption and effectiveness of individual and/or public health cessation programs,^[61] there is a second category of biomarkers specific to the development of cancer. Such studies are even fewer in number, and include hypermethylation^[62] or general inflammatory response biomarkers.^[63] The inherent difficulty in the latter approach is the multitude of different betel nut preparations that are available for

consumption, as well as the tendency of user populations to use such formulations interchangeably, and as such might be difficult to tease apart when trying to correlate to specific biomarker profiles.

PLANNING FOR THE FUTURE

Although the use of betel nut has been characterized as a risk factor for many oral and esophageal cancers, to date, the exact role and mechanisms in oral carcinogenesis remain poorly understood in comparison with other popular addictive substances, such as tobacco and caffeine. As such, existing gaps and opportunities are summarized in the following paragraphs.

Systematic Use and Negative Side Effects

Although betel nut is increasingly available globally through international trade, their use remains highly prevalent in the Asia-Pacific region. However, to date there do not exist highly detailed studies in terms of the regional levels of use, including the admixtures with other products (such as tobacco), as there is wide regional variation.^[64,65] There are many studies that report the levels of use for communities and populations, and for specific time periods, as mentioned previously. For example, epidemiologic studies showed that the prevalence of use varied widely between 0.2% and 60.8% in Cambodian population groups in 1995, whereas a prevalence of 21.9% was reported in a Malaysian population in 1995.^[66] However, a more consistent approach is lacking in terms of a population cohort that will be followed over a longer period and be validated against comparable protocols or cohorts. Doing so at the population level would provide granularity on the dose-dependent correlation between use levels and different impacts and will provide some indication on potential other confounders.

Furthermore, at the personal level, betel quid and areca nut are associated with negative health side effects on the cardiovascular, nervous, gastrointestinal, metabolic, respiratory, and reproductive systems.^[67-70] The creation of population cohorts that are representative of different national or regional populations and socioeconomic strata would be critical in establishing the exact level of association between betel nut use and these potential side effects in a dose-dependent manner at the individual level,^[66] as well as the most appropriate biomarkers that would need to be monitored. The existing wealth of scientific literature that allowed for the International Agency for Research on Cancer classifications will be further supported by the current active research activities on the subject in Southeast Asia. Finally, one should also consider the psychological effects of regular use, as long-term use has been associated with effects in specific populations.^[71-73] For example, in Taiwan, betel nut use is empirically considered to lead to sustained attention and inhibitory controls that have been impaired after one night of deprived sleep. Following sleep deprivation,

chewing betel nut can immediately improve habitual chewers' selective attention.^[74] As such, betel nut use might be habitual for particular types of employment or lifestyle. For instance, there are reports in Taiwan concerning the habit of taxi drivers chewing betel nut to stay awake during long shifts.^[72]

Potential Positive Side Effects

Betel nut is used as a compound in traditional medicine in India and throughout Southeast Asia to treat multiple disorders, such as inflammation (e.g., gingivitis, conjunctivitis, edema), flatulence, diarrhea and dysentery, hyperemesis in pregnancy, dysuria, and high blood pressure.^[75–77] It also reportedly possesses astringent, analgesic, and aphrodisiac properties.^[78,79] Furthermore, *Areca catechu* powder has been applied topically as an anti-inflammatory remedy or the nut is made into ash for local application. It is also used as collyrium, in a more refined form, to provide relief in conjunctivitis and epiphoria.^[80] There exist also a number of compound preparations containing *Areca catechu*, such as Ma'jun Supari and Ma'jun Mochrus, which are applied topically in wound healing.^[81,82]

Traditional Indian medicine uses betel nut as one of the treatments for glaucoma, as a mild stimulant, and as a digestive aid.^[83] Furthermore, in veterinary medicine, an extract of areca is used as herbal method for expelling tapeworms in cattle, dogs, and horses; to empty animals' bowels; and for treating intestinal colic in horses.^[84,85] However, none of the treatments have experienced any systematic research attempts, neither at a population nor at an individual level. Therefore, the systematic, long-term view for a potential positive side effect is currently absent.

Socioeconomic Aspects

The socioeconomic aspects of betel nut consumption have been largely overlooked. There exist very few narrative reviews, focusing mostly on the Indian market, and conducted to establish some of these features of areca nut consumption.^[24,86,87] There are also studies that provide snapshots for individual locations across Southeast Asia.^[88–90] Although these studies form useful indications, this is not sufficient information nor evidence to consider the socioeconomic aspects in depth, such that an effective public health policy can be informed and targeted to the most vulnerable groups. For example, there are no socioeconomic studies in the international, scientific, peer-reviewed literature regarding China. Although studies on isolated communities in Papua-New Guinea provide a useful context in terms of changing rural cultivation practices,^[90,91] they cannot be generalized to the wider Southeast Asian context. Some of the challenges in trying to acquire a full overview of the socioeconomic aspects of betel nut, are that South Asian economies are at different stages of development and have varying and very different areca nut cultivation practices. In addition, they have very different cultural

beliefs, employment opportunities, and marketing strategies, coupled with a lack of detailed data for a number of countries. Thus, there are few studies of narrow financial impacts, but not on a potential wider contribution.^[92,93] Interestingly, this variation is reflected in secondary markets too. For example, the retail practice among the South Asian communities of the United Kingdom was found to reflect the diverse consumer practices and price structures that are current in their countries of origin.^[94]

It is believed that India is the largest producer of areca nuts in the world accounting for more than 50% of global production (Food and Agriculture Organization, average annual production data from 1994–2020). India is followed by Myanmar, Indonesia, Bangladesh, China, and Taiwan, by approximately 6–9% for each location, and much smaller volumes (less than 2.5% each) are grown in Sri Lanka, Thailand, Nepal, and Bhutan. However, the lack of consistent published evidence makes those relative amounts and their year-on-year fluctuation difficult to validate.^[95]

Traditional Medicinal Aspects

In China, the first report of the TCM properties of betel nut and betel leaf use was reported by the Portuguese ambassador to China, indeed during the very first ambassador mission, in a letter to King Manuel I in 1516.^[96] As such, betel nut constitutes a mainstay component of TCM. Currently, the southern part of China, especially Hainan, is the main production and consumption area for betel nut.^[97] Betel nut is part of the gamut of TCM compounds used to treat parasitic diseases, various gastrointestinal disorders (abdominal distension, abdominal pain, dyspepsia, and diarrhea), and jaundice.^[98] Ongoing studies in China, driven by such TCM observations are continuing to identify active ingredients (e.g., alkaloids) with potential therapeutic properties.^[99–101] As one of the main TCM uses is for gastrointestinal conditions, an area of study has developed relating to the effects of betel nut use on the microbiome. It has been shown that there are distinct changes to the microbiome of regular betel nut users, as anticipated; however, the microbiome alterations have not been definitively correlated with either a negative or positive side effect for the users themselves.^[97] Last, betel nut is one of the ingredients used to prescribe treatment for respiratory-related infections, according to most recent published guidelines in Chinese medicine.^[102]

Modern Chinese pharmacology shows that betel nut use can entail potential and varying pharmacologic properties, including antifatigue, antioxidant, antibacterial, antifungal, antihypertensive, antidepressant, anti-inflammatory, analgesic, and antiallergic properties; betel nut also promotes digestive function, inhibits platelet aggregation, and regulates blood glucose and blood lipids.^[79] Therefore, there exist strong arguments for the further socioeconomic study of betel nut for

potential identification of novel pharmaceutical products. For example, preliminary studies have shown a consistent positive effect for intestinal nematodes, such that TCM provides an alternative opportunity for using locally grown produce to support pharmaceutical production in resource-restricted settings.^[103] Last, it is important to include the psychoactive substances in this review of potential therapeutic agents, as indications exist that betel nut components might be useful in the case of developing novel antidepressive and anti-epileptic active compounds.^[104,105]

Future Biomarker Research

The pursuit of biomarkers identification in relation to betel nut remains at early stages, as compared with carcinogenesis biomarkers in other tissues (e.g., breast cancer). The recency of scientific discoveries is one of the reasons for this, as is the tissue type in which the detection is most likely to take place, that is, the saliva, which presents challenges in terms of biological variation (e.g., viscosity) and, thus, standardization of sampling.^[58,59] Furthermore, there are different types of biomarkers pursued, reflecting the different needs. These can be biomarkers indicative of level of use, and biomarkers relating directly to carcinogenicity or both. The challenge posed is that many of the biomarkers proposed so far (e.g., nicotine) might be highly sensitive, but they are not specific enough.^[106,107] Thus, further concerted efforts are required in this direction before a potential breakthrough can be achieved.

Setting Standards

Considering the risks associated with betel nut use, the attempts to regulate consumption would need to follow a more structured framework rather than rely on individual local or national initiatives. Betel leaf is perishable, and the preparation of betel quid is somewhat complex. Hence, over the past few decades, new formulations have emerged as commercial betel quid substitutes, such as a flavored and sweetened dry mixture of betel nut, catechu, and slaked lime either with tobacco (gutkha or khaini) or without tobacco (paan masala). These more standardized products with longer shelf life have become increasingly popular in India, where the largest regular use population exists.^[108] Further variations exist, depending on the type of preparation of the actual plant product, and the different combinations of adjoint materials (e.g., tobacco, lime). All these make standardization particularly difficult, both with respect to the scientific studies, as well as for informing financial and socioeconomic policies.^[109] Thus, the need for standardization remains acute internationally. This has been reflected in recent studies in China, where the wider public, including regular users, expressed the need for wider regulation in view of the identified risks relating to betel nut use.^[110]

CONCLUSION

Betel nut and products derived from it are widely used as a masticatory among various communities, and in several countries across the world, as a socially endorsed habit, despite its addictive properties. Over a long period, several additives have been added to a simple betel nut preparation, thus creating the betel quid and encompassing chewing tobacco and other agents in the preparation, in variable amounts and combinations. The popularity of betel nut has subsequently led to the industrial preparations of convenient substitutes of the betel nut or betel quid in the form of paan masala, gutkha, and similar industrial concoctions in several countries across Southeast Asia and globally.

The wide variation of products available in the global markets, as well as the lack of standardization, have impeded the scientific progress toward understanding in detail the physiology, biochemistry, and even potential positive effects of betel nut use. There are sufficient data to link long-term betel nut use to carcinogenicity; however, there are many aspects still suboptimally investigated, such as biomarker development, and psychological, socioeconomic, and financial aspects. Furthermore, aspects relating to chemical makeup and traditional pharmacology remain to be studied in depth, as well as different formulations of the final product, which might contain reduced or chemically extracted arecoline options. Furthermore, despite attempts to increase public awareness with mass campaigns, particularly in India, there has been little reduction in the betel nut habit. This suggests a need for better targeted public health measures and communication strategies; however, those can only materialize once the current research gaps and challenges have been addressed.

References

- Hernandez BY, Zhu X, Goodman MT, et al. Betel nut chewing, oral premalignant lesions, and the oral microbiome. *PLoS One*. 2017;12:e0172196.
- Gupta PC, Warnakulasuriya S. Global epidemiology of areca nut usage. *Addict Biol*. 2002;7:77–83.
- Papke RL, Horenstein NA, Stokes C. Nicotinic activity of arecoline, the psychoactive element of “betel nuts”, suggests a basis for habitual use and anti-inflammatory activity. *PLoS One*. 2015;10:e0140907.
- Mortazavi H, Baharvand M, Mehdipour M. Oral potentially malignant disorders: an overview of more than 20 entities. *J Dent Res Dent Clin Dent Prospects*. 2014;8:6–14.
- Spittel RL. Betel-chewing and cancer. *Br Med J*. 1924;1:158.
- Iyer MAK. Betel-chewer's cancer. *Ind Med Gaz*. 1926;61:206.
- Eisen MJ. Betel chewing among natives of the Southwest Pacific Islands; lack of carcinogenic action. *Cancer Res*. 1946;6:139–141.
- Veliath GD. The problem of cancer in India. *J Indian Med Assoc*. 1950;19:397–399.
- Mendelson RW. Betel nut chewer's cancer. *U S Armed Forces Med J*. 1951;2:1371–1375.

10. Gerry RG, Smith ST, Calton ML. The oral characteristics of Guamanians including the effects of betel chewing on the oral tissues. *Oral Surg Oral Med Oral Pathol.* 1952;5:762–781.
11. Gerry RG, Smith ST, Calton ML. The oral characteristics of Guamanians including the effects of betel chewing on the oral tissues. II. Diseases of the oral mucous membranes and dental supporting tissues in Guamanians. *Oral Surg Oral Med Oral Pathol.* 1952;5:884–894; contd.
12. Gerry RG, Smith ST, Calton ML. The oral characteristics of Guamanians including the effects of betel chewing on the oral tissues. III. *Oral Surg Oral Med Oral Pathol.* 1952;5:1004–1011; concl.
13. Burton-Bradley BG. Papua and New Guinea transcultural psychiatry: some implications of betel chewing. *Med J Aust.* 1966;2:744–746.
14. Chang KM. Betel nut chewing and mouth cancer in Taiwan. First report: survey of disposition of mouth cancer in Taiwan. *Tsa Chih Gaoxiong Yi Xue Yuan Tong Xue Hui.* 1964;63:437–448.
15. Chang KM. Betel nut chewing and mouth cancer in Taiwan. 2. Observation of the oral mucosa in the betel nut chewer. *Taiwan Yi Xue Hui Za Zhi.* 1966;65:79–85.
16. Fendell LD, Smith JR. Betel-nut-associated cancer: report of case. *J Oral Surg.* 1970;28:455–456.
17. Bachand RG. Betel chewing: some observations of the habit among the Vietnamese. *Dent Stud.* 1967;45:581–583 passim.
18. Waerhaug J. Prevalence of periodontal disease in Ceylon. Association with age, sex, oral hygiene, socio-economic factors, vitamin deficiencies, malnutrition, betel and tobacco consumption and ethnic group. Final report. *Acta Odontol Scand.* 1967;25:205–231.
19. Reddy DG, Anguli VC. Experimental production of cancer with betel nut, tobacco and slaked lime mixture. *J Indian Med Assoc.* 1967;49:315–318 passim.
20. Jüptner H. Clinical and experimental studies on the effects of intense betel chewing in the natives of Trobriand Islands (New Guinea) [in German]. *Z Tropenmed Parasitol.* 1968;19:254–257.
21. Marsden AT. Betel cancer in Malaya. *Med J Malaya.* 1960;14:162–165.
22. Forlen HP, Hornstein O, Stuetzgen G. Betel chewing and leukoplakia [in German]. *Arch Klin Exp Dermatol.* 1965;221:463–480.
23. Lee KW, Chin CT. The effects of betel-nut chewing on the buccal mucosa: a histological study. *Br J Cancer.* 1970;24:433–441.
24. Ahluwalia HS, Ponnampalam JT. The socio-economic aspects of betel-nut chewing. *J Trop Med Hyg.* 1968;71:48–50.
25. Engelkes G. Betel nuts and dental remedies. A brief look at ancient folk remedies [in German]. *Quintessenz.* 1969;20:165–166.
26. Engelkes G. Betel nuts and dental remedies [in German]. *Zahnarztl Prax.* 1969;20:156.
27. Suri K, Goldman HM, Wells H. Carcinogenic effect of a dimethyl sulphoxide extract of betel nut on the mucosa of the hamster buccal pouch. *Nature.* 1971;230:383–384.
28. Hamner JE 3rd, Reed OM. Betel quid carcinogenesis in the baboon. *J Med Primatol.* 1972;1:75–85.
29. Betel I, van den Berg KJ. Interaction of concanavalin A with rat lymphocytes. *Eur J Biochem.* 1972;30:571–578.
30. van den Berg KJ, Betel I. Increased transport of 2-aminoisobutyric acid in rat lymphocytes stimulated with concanavalin A. *Exp Cell Res.* 1973;76:63–72.
31. Arjungi KN. Areca nut: a review. *Arzneimittelforschung.* 1976;26:951–956.
32. Gemmell MA. The Styx field trial: a study on the application of control measures against hydatid disease caused by *Echinococcus granulosus*. *Bull World Health Organ.* 1968;39:73.
33. Ranadive KJ, Gothoskar SV, Rao AR, et al. Experimental studies on betel nut and tobacco carcinogenicity. *Int J Cancer.* 1976;17:469–476.
34. Mori H, Matsubara N, Ushimaru Y, Hirono I. Carcinogenicity examination of betel nuts and piper betel leaves. *Experientia.* 1979;35:384–385.
35. Abraham SK, Goswami V, Kesavan PC. A preliminary assessment of possible mutagenicity of betel nut and ingredients of the betel quid when administered alone or in combinations to larvae of *Drosophila melanogaster*. *Mutat Res.* 1979;66:261–266.
36. Burton-Bradley BG. Is “betel chewing” carcinogenic? *Lancet.* 1979;2:903.
37. Reddy MS, Naik SR, Bagga OP, Chuttani HK. Effect of chronic tobacco-betel-lime “quid” chewing on human salivary secretions. *Am J Clin Nutr.* 1980;33:77–80.
38. Stich HF, Stich W, Lam PP. Potentiation of genotoxicity by concurrent application of compounds found in betel quid: arecoline, eugenol, quercetin, chlorogenic acid and Mn²⁺. *Mutat Res.* 1981;90:355–363.
39. Gupta PC, Pindborg JJ, Mehta FS. Comparison of carcinogenicity of betel quid with and without tobacco: an epidemiological review. *Ecol Dis.* 1982;1:213–219.
40. de Costa C, Griew AR. Effects of betel chewing on pregnancy outcome. *Aust N Z J Obstet Gynaecol.* 1982;22:22–24.
41. Joo YJ, Newcombe D, Nosa V, Bullen C. Investigating betel nut use, antecedents and consequences: a review of literature. *Subst Use Misuse.* 2020;55:1422–1442.
42. Ferrari R. Writing narrative style literature reviews. *Medical Writing.* 2015;24:230–235.
43. Schramm G. Pharmacopeia of the People's Republic of China, 1953 edition [in German]. *Pharm Zentralhalle Dtschl.* 1955;94:173–175.
44. Calogero AE, Kamilaris TC, Gomez MT, et al. The muscarinic cholinergic agonist arecoline stimulates the rat hypothalamic-pituitary-adrenal axis through a centrally-mediated corticotropin-releasing hormone-dependent mechanism. *Endocrinology.* 1989;125:2445–2453.
45. Kamath VV, Satelur K, Komali Y. Biochemical markers in oral submucous fibrosis: a review and update. *Dent Res J (Isfahan).* 2013;10:576–584.
46. Chen YY, Fang WH, Wang CC, et al. Detrimental association between betel nut chewing and colorectal polyps in adult populations. *PLoS One.* 2018;13:e0206383.
47. Chou CY, Cheng SY, Liu JH, et al. Association between betel-nut chewing and chronic kidney disease in men. *Public Health Nutr.* 2009;12:723–727.
48. Chechlinska M, Kowalewska M, Nowak R. Systemic inflammation as a confounding factor in cancer biomarker discovery and validation. *Nat Rev Cancer.* 2010;10:2–3.
49. Stich HF, Anders F. The involvement of reactive oxygen species in oral cancers of betel quid/tobacco chewers. *Mutat Res.* 1989;214:47–61.
50. Liu YJ, Peng W, Hu MB, et al. The pharmacology, toxicology and potential applications of arecoline: a review. *Pharm Biol.* 2016;54:2753–2760.

51. Das A, Giri S. A review on role of arecoline and its metabolites in the molecular pathogenesis of oral lesions with an insight into current status of its metabolomics. *Prague Med Rep.* 2020;121:209–235.
52. IARC Monographs Vol 128 Group. Carcinogenicity of acrolein, crotonaldehyde, and arecoline. *Lancet Oncol.* 2021;22:19–20.
53. Chang MC, Ho YS, Lee PH, et al. Areca nut extract and arecoline induced the cell cycle arrest but not apoptosis of cultured oral KB epithelial cells: association of glutathione, reactive oxygen species and mitochondrial membrane potential. *Carcinogenesis.* 2001;22:1527–1535.
54. Shih LJ, Wang JY, Jheng JY, et al. Betel nut arecoline induces different phases of growth arrest between normal and cancerous prostate cells through the reactive oxygen species pathway. *Int J Mol Sci.* 2020;21:9219.
55. Valavanidis A, Vlachogianni T, Fiotakis C. 8-hydroxy-2'-deoxyguanosine (8-OHdG): a critical biomarker of oxidative stress and carcinogenesis. *J Environ Sci Health C Environ Carcinog Ecotoxicol Rev.* 2009;27:120–139.
56. Ji WT, Yang SR, Chen JY, et al. Arecoline downregulates levels of p21 and p27 through the reactive oxygen species/mTOR complex 1 pathway and may contribute to oral squamous cell carcinoma. *Cancer Sci.* 2012;103:1221–1229.
57. Shih YH, Chiu KC, Wang TH, et al. Effects of melatonin to arecoline-induced reactive oxygen species production and DNA damage in oral squamous cell carcinoma. *J Formos Med Assoc.* 2021;120(1 Pt 3):668–678.
58. Franke AA, Mendez AJ, Lai JF, et al. Composition of betel specific chemicals in saliva during betel chewing for the identification of biomarkers. *Food Chem Toxicol.* 2015;80:241–246.
59. Franke AA, Li X, Lai JF. Pilot study of the pharmacokinetics of betel nut and betel quid biomarkers in saliva, urine, and hair of betel consumers. *Drug Test Anal.* 2016;8:1095–1099.
60. Franke AA, Biggs L, Yew JY, Lai JF. Areca alkaloids measured from buccal cells using DART-MS serve as accurate biomarkers for areca nut chewing. *Drug Test Anal.* 2019;11:906–911.
61. Franke AA, Lai JF, Kawamoto CT, et al. University of Hawaii 'i Cancer Center connection: Areca (betel) nut consumption: an underappreciated cause of cancer. *Hawaii J Med Public Health.* 2014;73:400.
62. Islam S, Uehara O, Matsuoka H, et al. DNA hypermethylation of sirtuin 1 (SIRT1) caused by betel quid chewing—a possible predictive biomarker for malignant transformation. *Clin Epigenetics.* 2020;12:12.
63. Chechlinska M, Kowalewska M, Nowak R. Systemic inflammation as a confounding factor in cancer biomarker discovery and validation. *Nat Rev Cancer.* 2010;10:2–3.
64. World Health Organization. *Review of Areca (Betel) Nut and Tobacco Use in the Pacific: A Technical Report.* Manila: WHO Regional Office for the Western Pacific; 2012.
65. Lee CH, Ko AM, Warnakulasuriya S, et al. Intercountry prevalences and practices of betel-quid use in south, southeast and eastern Asia regions and associated oral preneoplastic disorders: an international collaborative study by Asian betel-quid consortium of south and east Asia. *Int J Cancer.* 2011;129:1741–1751.
66. Sharan RN, Mehrotra R, Choudhury Y, Asotra K. Association of betel nut with carcinogenesis: revisit with a clinical perspective. *PLoS One.* 2012;7:e42759.
67. Lin WY, Pi-Sunyer FX, Liu CS, et al. Betel nut chewing is strongly associated with general and central obesity in Chinese male middle-aged adults. *Obesity (Silver Spring).* 2009;17:1247–1254.
68. Chu NS. Neurological aspects of areca and betel chewing. *Addict Biol.* 2002;7:111–114.
69. Chen TC, Wu CT, Ko JY, et al. Clinical characteristics and treatment outcome of oropharyngeal squamous cell carcinoma in an endemic betel quid region. *Sci Rep.* 2020;10:526.
70. Garg A, Chaturvedi P, Gupta PC. A review of the systemic adverse effects of areca nut or betel nut. *Indian J Med Paediatr Oncol.* 2014;35:3–9.
71. Yen HY, Chen PH, Ko YC, et al. Betel quid chewing, personality and mood: betel quid chewing associated with low extraversion and negative mood. *Subst Use Misuse.* 2018;53:1782–1787.
72. Ho MC, Li Rh, Tang Tc. Betel nut chewing effects on sustained attention and inhibitory control after sleep deprivation. *Aust J Psychol.* 2015;67:222–230.
73. Osborne PG, Chou TS, Shen TW. Characterization of the psychological, physiological and EEG profile of acute betel quid intoxication in naïve subjects. *PLoS One.* 2011;6:e23874.
74. Ho MC, Wang CK. The effect of betel nut chewing on contour and object masking. *Atten Percept Psychophys.* 2011;73:2583–2593.
75. Nadkarni KM. *Indian Materia Medica, 3rd ed.* Popular Prakashan, 1986.
76. Gilani AH, Ghayur MN, Saify ZS, et al. Presence of cholinomimetic and acetylcholinesterase inhibitory constituents in betel nut. *Life Sci.* 2004;75:2377–2389.
77. Duke JA. *Handbook of Medicinal Herbs.* CRC Press; 2002.
78. Khan S, Mehmood MH, Ali AN, et al. Studies on anti-inflammatory and analgesic activities of betel nut in rodents. *J Ethnopharmacol.* 2011;135:654–661.
79. Peng W, Liu YJ, Wu N, et al. *Areca catechu* L. (Arecaceae): a review of its traditional uses, botany, phytochemistry, pharmacology and toxicology. *J Ethnopharmacol.* 2015;164:340–356.
80. Chowdhury U, Baruah PK. Betelvine (*Piper Betle* L.): a potential source for oral care. *Curr Bot.* 2020;11:87–92.
81. Gilani AH, Aziz N, Khurram IM, et al. The presence of cholinomimetic and calcium channel antagonist constituents in *Piper betle* Linn. *Phytother Res.* 2000;14:436–442.
82. Pinn G. Traditional medical treatments III: Betel nut (*Areca catechu*). *Annals of the ACTM.* 2005;6:13–14.
83. Ahuja S, Ahuja U. Betel leaf and betel nut in India: History and uses. *Asian Agrihist.* 2011;15:13–35.
84. Chung HL, Hou TC, Huang TY, Weng HC. Areca nut (betel nut) and oleoresin of *Aspidium* in the treatment of intestinal taeniasis. *Chin Med J.* 1951;69:76–79.
85. Ouyang C, Kao HC. Treatment of intestinal cestodiasis with areca nut by the transduodenal method. *Chin Med J.* 1951;69:218–220.
86. Croucher R, Islam S. Socio-economic aspects of areca nut use. *Addict Biol.* 2002;7:139–146.
87. Arora M, Shrivastava S, Mishra VK, Mathur MR. Use of betel quid in India from 2009 to 2017: an epidemiological analysis of the Global Adult Tobacco Survey (GATS). *Subst Use Misuse.* 2020;55:1465–1471.
88. Tham J, Sem G, Sit E, Tai M. A scientific and socio-economic review of betel nut use in Taiwan with bioethical reflections. *Asian Bioethics Review.* 2017;9:401–414.

89. Khan MS, Bawany FI, Shah SR, et al. Comparison of knowledge, attitude and practices of betelnut users in two socio-economic areas of Karachi. *J Pak Med Assoc.* 2013;63:1319–1325.
90. Senn M, Baiwog F, Winmai J, et al. Betel nut chewing during pregnancy, Madang province, Papua New Guinea. *Drug Alcohol Depend.* 2009;105:126–131.
91. Ulijaszek SJ. Socio-economic factors associated with physique of adults of the Purari delta of the Gulf Province, Papua New Guinea. *Ann Hum Biol.* 2003;30:316–328.
92. Chen SH, Lee JM, Liu HH, et al. The cross-effects of cigarette and betel nut consumption in Taiwan: have tax increases made a difference? *Health Policy Plan.* 2011;26:266–273.
93. Pratt S. The challenge of betel nut consumption to economic development : a case of Honiara, Solomon Islands. *Asia Pacific Development Journal.* 2014;21:103–120.
94. Núñez-de la Mora A, Jesmin F, Bentley GR. Betel nut use among first and second generation Bangladeshi women in London, UK. *J Immigr Minor Health.* 2007;9:299–306.
95. Food and Agriculture Organization of the United Nations. Production crops: areca/nuts. Accessed July 18, 2022. www.fao.org/faostat/en/#data/QCL/visualize
96. Cagle H. *Assembling the Tropics: Science and Medicine in Portugal's Empire.* Cambridge University Press; 2018.
97. Ying L, Yang Y, Zhou J, et al. Effect of chewing betel nut on the gut microbiota of Hainanese. *PLoS One.* 2021;16:e0258489.
98. Zhao X, Davey G. Areca nut use among a Chinese ethnic minority, and its health implications. *Subst Use Misuse.* 2020;55:1519–1524.
99. Cao M, Yuan H, Daniyal M, et al. Two new alkaloids isolated from traditional Chinese medicine Binglang the fruit of *Areca catechu*. *Fitoterapia.* 2019;138:104276.
100. Yan D, Peng W, Liu Y, et al. Spectrum-effect relationships between high performance liquid chromatography fingerprints and bioactivities of charred areca nut. *Trop J Pharm Res.* 2016;15:1017–1024.
101. Efferth T, Li PC, Konkimalla VS, Kaina B. From traditional Chinese medicine to rational cancer therapy. *Trends Mol Med.* 2007;13:353–361.
102. Huang K, Zhang P, Zhang Z, et al. Traditional Chinese Medicine (TCM) in the treatment of COVID-19 and other viral infections: efficacies and mechanisms. *Pharmacol Ther.* 2021;225:107843.
103. Zhou H. Treatment methods of traditional chinese medicine for infection with *Ascaris lumbricoides* and other nematodes. In Mehlhorn H, Wu Z, Ye B, Eds.; *Treatment of Human Parasitosis in Traditional Chinese Medicine.* Springer Berlin, 2014; pp 203–213.
104. Yang Y, Huang H, Cui Z, et al. UPLC-MS/MS and network pharmacology-based analysis of bioactive anti-depression compounds in betel nut. *Drug Des Devel Ther.* 2021;15:4827–4836.
105. Wu M, Fang M, Hu Y, Wang X. Four types of traditional Chinese medicine inducing epileptic seizures. *Seizure.* 2012;21:311–315.
106. Chang YJ, Muthukumaran RB, Chen JL, et al. Simultaneous determination of areca nut-and tobacco-specific alkaloids in saliva by LC-MS/MS: distribution and transformation of alkaloids in oral cavity. *J Hazard Mater.* 2022;426:128116.
107. Franke AA, Li X, Custer LJ, Lai JF. Chemical markers for short-and long-term areca nut exposure. *Subst Use Misuse.* 2020;55:1395–1402.
108. Nair U, Bartsch H, Nair J. Alert for an epidemic of oral cancer due to use of the betel quid substitutes gutkha and pan masala: a review of agents and causative mechanisms. *Mutagenesis.* 2004;19:251–262.
109. Patidar KA, Parwani R, Wanjari SP, Patidar AP. Various terminologies associated with areca nut and tobacco chewing: a review. *J Oral Maxillofac Pathol.* 2015;19:69–76.
110. Tang Q, He L. A discourse analysis on betel nut chewing in Hunan Province, China. *J Psychoactive Drugs.* 2021;53:40–46.